Destiny Pharma upbeat on recent study into mupirocin alternative
18th Oct 2021 09:25
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said on Monday that a major US hospital-based clinical trial lent "strong support" for the potential of its 'XF-73' nasal product as an alternative to mupirocin in the treatment of Staphylococcus aureus infections.
Read moreDestiny Pharma's China partner starts new XF-73 programme
27th Sep 2021 10:10
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced on Monday that its China regional partner and investor, China Medical System Holdings (CMS), is establishing a new programme with 'XF-73' targeting the prevention and treatment of superficial skin infections caused by bacteria.
Read moreDestiny Pharma reports positive secondary data on 'XF-73'
2nd Aug 2021 11:34
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced additional, "strong" data from its recent phase 2b clinical trial on Monday.
Read moreDestiny Pharma inks research deal with US Veterans' Affairs
6th Jul 2021 10:35
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced a cooperative research and development agreement with the US Department of Veterans' Affairs on Tuesday, to support studies focusing on identifying new attributes for 'NTCD-M3' - a novel microbiome therapeutic being developed to reduce the recurrence of Clostridioides difficile infections in the gut.
Read moreDestiny Pharma reports positive progress on lead clinical programme
2nd Jun 2021 10:26
(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive progress with its lead clinical programme, 'NTCD-M3', on Wednesday.
Read moreDestiny Pharma meets recruitment deadline for XF-73 trial
5th Jan 2021 11:21
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced on Tuesday that its XF-73 phase 2b clinical trial was fully recruited by 31 December, meeting the target timeline set for the programme.
Read moreSecond Covid wave slows patient recruitment for Destiny Pharma
12th Oct 2020 14:31
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma updated the market on its 'XF-73' phase 2b clinical study with 101 patients on Monday, out of the target of 125 now recruited.
Read moreDestiny Pharma enters collaboration deal with SporeGen
7th Sep 2020 08:57
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has entered into a collaboration agreement with SporeGen, it announced on Monday, which is a UK biotechnology company working on Bacillus and its applications.
Read moreDestiny Pharma awarded grant for Cardiff research collaboration
9th Jun 2020 15:51
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has been jointly awarded a National Biofilms Innovation Centre (NBIC) grant to fund a research collaboration with Cardiff University, it announced on Tuesday.
Read moreDestiny Pharma pleased with latest XF-73 results at it proceeds with next phase
16th Oct 2019 14:48
(Sharecast News) - Clinical stage biotechnology company Destiny Pharma reported on the publication of results from a positive phase 1 clinical study in 60 healthy United States volunteers using a nasal gel formulation of its lead drug, XF-73 (exeporfinium chloride), on Wednesday.
Read moreDestiny Pharma 'well funded' despite wider loss
9th Apr 2019 09:32
(Sharecast News) - Destiny Pharma on Tuesday reported a wider annual loss as it increased research and development costs, although the company is "well funded" through to the second half of next year.
Read moreDestiny Pharma sees success in latest trial of XF-73 nasal gel
28th Jan 2019 10:39
(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive data and the non-irritant classification for its XF-73 nasal gel on Monday.
Read moreDestiny Pharma leaps on £1.6m grant and UK-China collaboration
25th Jan 2019 10:58
(Sharecast News) - Destiny Pharma jumped on Friday after being awarded funding of up to £1.6m from a collaboration established under the UK-China AMR grant fund.
Read moreDestiny Pharma helps with new bioindustry association videos
19th Oct 2018 14:54
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma noted the launch of a series of videos and explainer documents from the UK BioIndustry Association (BIA) celebrating UK bioscience and revealing the research and development taking place in biotech companies around the UK on Friday.
Read moreChairman of Destiny calling time after 15 years with pharma firm
6th Sep 2018 10:32
(Sharecast News) - Clinical stage biotechnology firm Destiny Pharma revealed on Thursday that long-time chairman Nigel Rudd was stepping down from the board on 31 December after eight years.
Read more